SCHEMBL9890033

SCHEMBL9890033

CC(=O)Nc1cc(-c2cc(C(C)=O)c(-c3ccccc3Cl)o2)c(C)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 3/20 0.44
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
LIMK1 P53667 1/20 0.40
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
ABL1 P00519 5/20 0.38
PTK2 Q05397 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108874 0.93 PIK3C3 (0.46) PIK3C3JAK2JAK1TYK2TDP1
SCHEMBL9107473 0.92 PIK3C3 (0.43) PIK3C3JAK2JAK1TYK2TDP1
SCHEMBL9888609 0.91 RAB9A (0.44) PIK3C3JAK2JAK1TYK2TDP1
SCHEMBL9108275 0.91 PIK3C3 (0.42) PIK3C3JAK2JAK1TYK2TDP1
SCHEMBL9113709 0.90 PIK3C3 (0.42) PIK3C3TDP1RAB9AKDM4EMEN1
SCHEMBL9106554 0.89 HPGD (0.42) PIK3C3JAK2JAK1TYK2TDP1
SCHEMBL9109616 0.88 PIK3C3 (0.42) PIK3C3JAK2JAK1TYK2TDP1
SCHEMBL9107884 0.87 KDM4E (0.40) PIK3C3TDP1RAB9AKDM4EMEN1
SCHEMBL9107516 0.86 MAPT (0.43) PIK3C3TDP1RAB9AKDM4EMEN1
SCHEMBL9890501 0.85 KMT2A (0.39) PIK3C3TDP1RAB9AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2012021615-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 PIK3C3 52/4885JAK2 459/4885JAK1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.